User Login
|
Create Account
|
Contact Us
Facebook
Instagram
X
LinkedIn
TikTok
Home
Browse By Tumor Type
Upcoming Events
About Us
Subscribe
CME Post-Tests
Home
We've determined that you are accessing this site using a mobile device. Please select which version of the site you would like to browse.
RTP On Demand: Current Controversies and Emerging Data Sets in Follicular Lymphoma and Chronic Lymphocytic Leukemia
Home
CME test
CME information and faculty disclosures
Select publications
Rituximab combined with lenalidomide (R squared) in untreated lymphoma
4:25 minutes.
NEXT VIDEO:
Type II anti-CD20 monoclonal antibody obinutuzumab in CLL
Related videos:
BRIGHT and StiL NHL1-2003 studies of bendamustine/rituximab versus rituximab/chemotherapy in NHL
Rituximab schedule and maintenance in FL
Type II anti-CD20 monoclonal antibody obinutuzumab in CLL
Novel agents in FL and CLL: BTK inhibitors
Targeted therapies in lymphomas and CLL: BTK, Syk and PI3Kδ inhibitors
Case 1: 59-year-old woman with Stage IE, Grade 3A FL
Case 2: 48-year-old woman diagnosed 10 years ago with FL
Case 3: 62-year-old man with Grade 1 FL and Stage IIA colon adenocarcinoma
Case 4: 60-year-old man with asymptomatic progression of CLL